Kiniksa Pharmaceuticals International, plc
KNSA
$40.59
$0.521.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.34% | 13.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.34% | 13.80% | |||
| Cost of Revenue | 17.66% | 15.19% | |||
| Gross Profit | 13.42% | 12.67% | |||
| SG&A Expenses | 4.78% | 7.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.78% | 9.74% | |||
| Operating Income | 19.15% | 51.90% | |||
| Income Before Tax | 18.71% | 46.98% | |||
| Income Tax Expenses | 72.88% | -28.20% | |||
| Earnings from Continuing Operations | 3.38% | 108.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.38% | 108.83% | |||
| EBIT | 19.15% | 51.90% | |||
| EBITDA | 18.94% | 50.68% | |||
| EPS Basic | 1.61% | 106.64% | |||
| Normalized Basic EPS | 16.69% | 45.41% | |||
| EPS Diluted | 0.00% | 109.09% | |||
| Normalized Diluted EPS | 15.65% | 43.51% | |||
| Average Basic Shares Outstanding | 1.74% | 1.09% | |||
| Average Diluted Shares Outstanding | 2.69% | 2.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||